Does Debio-025 reduce hepatitis C viral load in patients coinfected with hepatitis C and human immunodeficiency virus?
Preliminary human data suggests that cyclophilin inhibition with Debio-025 reduces hepatitis C viral load in HIV/HCV coinfected patients.
Debio-025 induced a strong drop in CypB levels, coinciding with the decrease in hepatitis C viral load. These are the first preliminary human data supporting the hypothesis that CypB may play an important role in hepatitis C virus replication and that Cyp inhibition is a valid target for the development of anti-hepatitis C drugs.
Flisiak et al. (Thu,) studied this question.